$IPCI Company News Intellipharmaceutics' Oxycodone

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$IPCI Company News

Intellipharmaceutics' Oxycodone Program to Prevent Overdose - Analyst Blog 5:10 p.m. Aug. 29, 2014 - Zacks.com
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert - Tale of the Tape 11:14 a.m. July 29, 2014 - Zacks.com
Wall Street Is Overlooking Intellipharmaceutics- CFO Shameze Rampertab Tells Us Why 10:45 a.m. July 29, 2014 - Seeking Alpha
Why Intellipharmaceutics (IPCI) Stock Is Down Today 3:41 p.m. July 9, 2014 - TheStreet.com
IntelliPharmaCeutics International (IPCI) Crumbles: Stock Plunges by 13.3% - Tale of the Tape 8:30 a.m. July 9, 2014 - Zacks.com
Flamel Technologies SA (FLML) Soars: Stock Up 6.6% - Tale of the Tape 9:39 a.m. April 17, 2014 - Zacks.com
Tetraphase Slumps: TTPH Falls 10.3% in Session - Tale of the Tape 8:49 a.m. April 15, 2014 - Zacks.com
Flamel Technologies (FLML) Jumps: Stock Adds 9.8% in Session - Tale of the Tape 8:51 a.m. April 10, 2014 - Zacks.com
Catalyst Pharmaceutical Partners Inc. (CPRX) Jumps: Stock Up 8.6% - Tale of the Tape 8:51 a.m. April 4, 2014 - Zacks.com
Corcept Therapeutics (CORT) Jumps: Stock Adds 5.4% in Session - Tale of the Tape 9:39 a.m. March 31, 2014 - Zacks.com
IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape 8:51 a.m. March 21, 2014 - Zacks.com
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? - Tale of the Tape 7:44 a.m. March 21, 2014 - Zacks.com
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape 8:51 a.m. March 11, 2014 - Zacks.com
Strong Demand For Resistance Technology Bodes Well For IntelliPharmaCeutics 1:06 p.m. Dec. 17, 2013 - Seeking Alpha
Thursday’s Biggest Stock Losers: SGOC, VJET, and More 5:56 a.m. Nov. 21, 2013 - InvestorPlace.com
Strength Seen in IntelliPharmaCeutics (IPCI): Stock Shoots 161.9% - Tale of the Tape 10:04 a.m. Nov. 20, 2013 - Zacks.com
Small Cap Stocks: Why IPCI Stock Went Bonkers 3:45 a.m. Nov. 20, 2013 - InvestorPlace.com
Alcatel-Lucent Left in the Lurch by Nokia and 2 More Heavily Traded Stocks to Follow 5:14 p.m. Nov. 19, 2013 - Wall St. Cheat Sheet
Intellipharmaceutics still Buy-rated following Focalin XR generic news 11:05 a.m. Nov. 19, 2013 - Seeking Alpha
Intellipharmaceutics nearly doubles on generic Focalin XR approval 9:31 a.m. Nov. 19, 2013 - Seeking Alpha


Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose Deterrence Technology 4:45 p.m. Aug. 28, 2014 - GlobeNewswire
Intellipharmaceutics Announces Second Quarter 2014 Results 6:01 p.m. July 7, 2014 - GlobeNewswire
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement 5:46 p.m. May 20, 2014 - GlobeNewswire
Pharma Stocks Technical Briefing -- Research on Forest Laboratories, Valeant Pharma, IntelliPharmaCeutics Intl., and Acura Pharma 8:09 a.m. May 8, 2014 - PR Newswire - PRF
Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes 5:39 p.m. March 21, 2014 - PR Newswire - PRF
Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014 5:00 p.m. March 19, 2014 - GlobeNewswire
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics 8:20 a.m. March 13, 2014 - PR Newswire - PRF
Intellipharmaceutics to Present at Two Upcoming Investor Conferences 6:00 p.m. March 4, 2014 - GlobeNewswire
Intellipharmaceutics Announces 2013 Year End Results 8:05 a.m. Feb. 18, 2014 - GlobeNewswire
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market 10:05 a.m. Feb. 4, 2014 - PR Newswire - PRF
Intellipharmaceutics Receives $3.1 Million From Par Pharmaceuticals, Inc. 8:00 a.m. Feb. 3, 2014 - GlobeNewswire
Healthcare Sector Announces Voluntary Recalls, Scheduled Presentations and Offering Programs - Research Report on Baxter, Incyte, Horizon Pharma, POZEN, and IntelliPharmaCeutics 9:00 a.m. Dec. 2, 2013 - PR Newswire
Intellipharmaceutics to Present at the 25th Annual Piper Jaffray Healthcare Conference 8:00 a.m. Dec. 2, 2013 - GlobeNewswire
Intellipharmaceutics Announces At-The-Market Offering of Common Shares 5:30 p.m. Nov. 27, 2013 - GlobeNewswire
Approved Acquisition, FDA Approvals, Senior Note Offerings, and Announcements by Drug Delivery Companies - Research Report on Elan, IntelliPharmaCeutics, Valeant Pharmaceuticals, Hospira, and Alkermes 9:00 a.m. Nov. 22, 2013 - PR Newswire
TrendingWallStreet.com Releases Trend Research on NNRX, NWBO, FMCC, and IPCI 1:17 a.m. Nov. 21, 2013 - ACCESSWIRE
TrendingWallStreet.com Releases Volume Coverage on NCT, VEND, PGLO, and IPCI 1:20 a.m. Nov. 20, 2013 - ACCESSWIRE
HZNP, FB, GRPN and IPCI added to NASDAQ Active Stock Watch List at GSR 11:11 a.m. Nov. 19, 2013 - ACCESSWIRE
Intellipharmaceutics / Par to Make Immediate Commercial Launch of 15 and 30 mg Generic Focalin XR(R) 5:35 p.m. Nov. 18, 2013 - GlobeNewswire
Intellipharmaceutics Announces Third Quarter 2013 Results 5:00 p.m. Oct. 1, 2013 - GlobeNewswire

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Enterprise Networking Set for Big Growth by 2032

Updated Category News Views 189

Enterprise Networking's Growth Trajectory When the digits start rolling in at a compound annual growth rate of a neat 10.1%, you know there's a story worth watching. This tale of enterprise networking gaining traction is a head-turner, anticipated to soar from $134.59 billion in 2026 to a hefty $239.92 billion by 2032. Hold onto your hats—there's a storm of change...

Continue Reading
Xi Jinping's Vision for China's Financial Evolution

Updated Category News Views 103

Xi's Blueprint for Financial Strength Xi Jinping isn't just whistling Dixie when it comes to reshaping China's financial landscape. His vision is about more than pushing paper; it's about embedding honesty, prudence, and traditional values into the very DNA of China's financial sector. When he talks about enhancing both hard and soft power, he’s thinking wider than...

Continue Reading
Yuhang's Innovative Tech: Journalists Get A Front Row Seat

Updated Category News Views 124

A Sneak Peek into Yuhang's Technological Leap Imagine strolling through a place where technology and nature coexist in harmony. That's exactly what journalists from around the globe got to experience during their recent jaunt to Yuhang District in Hangzhou. We're talking about reps from South Korea, Turkey, the U.S., and even Cuba getting a firsthand look at Yuhang's...

Continue Reading
November Oil Outlook: OPEC+ Steady, Key Earnings Ahead

Updated Category News Views 79

Oil's November Gambit: OPEC+ and U.S. Dynamics November's here, and boy, it's shaping up to be a wild one for the oil market. OPEC+ decided to stick with their oil production targets for December, leaving the supply faucets unchanged. This group, including big players like Saudi Arabia and Russia, met virtually and chose to hit the brakes on any changes just yet. With the...

Continue Reading
Emergys and Glean Rearrange AI Puzzle for Enterprises

Updated Category News Views 132

Enterprises on AI: From Dreams to Doing Alright, here’s a nugget for you: AI isn't just pie-in-the-sky jazz anymore. Some folks are finally bringing it down to Earth. Emergys, a player in digital transformation, is shaking hands with Glean, renowned for their enterprise AI chops, to turn enterprise chaos into clarity. It's all about squeezing out real returns and...

Continue Reading
Urenco's LEU+ Boosts Future Nuclear Reactor Options

Updated Category News Views 139

Urenco's Leap Forward with LEU+ Well, look who’s shaking up the nuclear scene—Urenco USA, that’s who. They’ve just churned out their first cylinder of low-enriched uranium plus (LEU+) at the National Enrichment Facility in Eunice, New Mexico. This isn’t just any regular Tuesday of uranium talk; it marks a seismic shift for nuclear fuel options in the Western...

Continue Reading
Ensign Group Faces Class Action Amid Stock Plummet

Updated Category News Views 117

Ensign Group's Recent Troubles Unraveled Let's set the scene: Ensign Group, once riding high at over $170 a share, finds itself knee-deep in allegations that'll make any investor squirm. Now, we're not just talking about a typical market fluctuation here – this is a real smackdown with an 8.2% drop, all thanks to some damning accusations. A Closer Look at Allegations...

Continue Reading
Helsinki's Christmas Market: Saunas and Sustainability

Updated Category News Views 101

Finnish Heat at a Christmas Market? It's not every day you hear about donning a swimsuit in freezing Helsinki. But this Christmas, that's exactly what's happening in their market. A classic Finnish sauna is set to take center stage, blending the chill of the festive season with legendary heat—a quirky mix that might just be the next big draw for tourists. A Different...

Continue Reading
StackRails Unleashes AI Power with Contextual Clarity

Updated Category News Views 25

AI's Blind Spots Exposed Let's get this straight—plugging AI into enterprise coding projects without context is like sending a blindfolded sprinter onto a city's marathon route. Sure, they'll move, but who knows what havoc they'll wreak along the way? That's where StackRails steps up to the plate, aiming to dispel the chaos with a robust grip on the bigger picture. The...

Continue Reading
PSEG Q3 2026: Mixed Earnings Amidst Storms and Stability

Updated Category News Views 101

Decoding PSEG's Q3 2026 Performance A company's quarterly performance can feel a bit like checking the weather: you are never quite sure what's coming your way. For PSEG's (NYSE: PEG) third quarter of 2026, the skies were full of mixed signals. Just looking at the headline earnings number, $0.76 per share in net income, there's a drop from last year's $1.24. That’s a...

Continue Reading

Top 5 Most Recently Viewed Articles

Legal Action Review for Lineage, Inc. Investors - Take Note

Updated Category News Views 122

Overview of Legal Issues Facing Lineage, Inc. Investors should be aware of important developments regarding Lineage, Inc. This leading company is currently facing a class action securities lawsuit. This news has garnered attention as it deeply impacts shareholders and signifies the need for vigilance within the investment community. What is the Class Action Lawsuit About?...

Continue Reading
Midnight Hub Investors Urged to Act on Class Action Opportunity

Updated Category News Views 102

Investors Alert: Class Action Lawsuit Opportunity for Midnight Hub NFT Holders In a significant development for investors affiliated with Midnight Hub, Bronstein, Gewirtz & Grossman, LLC has formally announced a riveting class action lawsuit directed at individuals who acquired ROOMS non-fungible tokens (NFTs) and Digital Nomads NFTs. These digital assets, issued by...

Continue Reading
Exploring the Synergy of AI and Blockchain in Finance

Updated Category News Views 229

The Transformative Power of AI and Blockchain In the rapidly evolving world of finance, the integration of artificial intelligence (AI) and blockchain technology is heralding a new era. As digital markets expand, the sheer volume and speed of data can be overwhelming for traditional processing methods. This is where artificial intelligence steps in, restructuring...

Continue Reading
TeraWatt Tech Snags Battery Vet Dr. Kang for Innovation Boost

Updated Category News Views 5

Next Big Leap in Battery Tech? Dr. Sunho Kang's arrival at TeraWatt Technology is the kind of news that makes folks in the energy sector sit up and take notice. With more than 25 years under his belt handling battery innovations from lab to factory floor, Kang's move smells like a game-changer for TeraWatt. If you don't know already, TeraWatt’s not just dabbling in...

Continue Reading
Nuvation Bio's Upcoming Results: Trading the Oncology Gamble?

Updated Category News Views 166

Nuvation Bio Inc. (NYSE: NUVB) is set to drop its financial results for Q4 and the full year of 2025 on March 2, 2026. Mark your calendars—this one could be a rollercoaster ride for traders. The oncology firm’s got a diversified pipeline packed with heavy-hitters like taletrectinib and safusidenib, but the real question is whether these treatments will convert into...

Continue Reading